New drug aims to cut opioid use after knee surgery

NCT ID NCT07548385

Recruiting now Symptom relief Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether Suzetrigine, a new pain medication, can improve pain control and reduce opioid use after total knee replacement. About 235 adults scheduled for knee surgery will be randomly assigned to receive either Suzetrigine or a placebo, in addition to standard pain care. The study measures how much opioid painkiller participants need and their pain scores on a 0-10 scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Suzetrigine (a new pain medication that blocks pain signals from nerves)
What this could lead to: If it works, this could provide a new option for managing pain after knee replacement, potentially reducing the need for opioids.
What could go wrong: This is a Phase 3 trial, but results may not show a significant benefit over existing treatments. The drug is still investigational and may have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-OPERATIVE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-OPERATIVE PAIN TOTAL KNEE REPLACEMENT SURGERY

Contacts and locations

Locations

Mount Sinai West
RECRUITING

New York, New York, 10019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.